Our method also determined the VAF of ovarian cancer‐related sites (KRAS‐G12R, NRAS‐G12C, and BRAF‐V600E) in clinical tissue and blood samples, enabling the discrimination between ovarian cancer patients and healthy volunteers. Here, NRAS is linked to ovarian carcinoma.